Menu

Study: IVF Media Affects Treatment Outcomes

Differences between cultures used for in vitro fertilization techniques can impact fertility and offspring health, researchers report.

Aug 24, 2016
Ben Andrew Henry

WIKIMEDIA, UMBERTO SALVAGNIN

Experts have been divided over whether the culture media in which eggs are fertilized during in vitro fertilization (IVF) have lasting impacts on embryonic development. In a paper published in Human Reproduction this week (August 23), researchers from the Maastricht University Medical Center in the Netherlands and their colleagues detail the first randomized controlled trial to compare two IVF culture media, finding that one of the preparations created more viable embryos and higher fertility rates than the other. Babies born using this culture also weighed about a third of a pound less, the team found. “It’s reasonable to believe that different media compositions can affect embryo development,” David Ball, an embryology lab director in Seattle who was not involved in the trial, told STAT News.

The clinics involved in the study stopped using the culture shown to produce fewer viable embryos, STAT reported, but the study only compared two of the roughly 20 IVF culture media commercially available.

The difficulty clinics face in choosing IVF media is bolstered by the fact that companies that produce cultures are not required to list the exact compositions of their products. The labels on culture media give ingredients without exact proportions, the researchers noted in their paper. Now that it’s known that this substrate can affect fertility and offspring health, “not knowing the exact composition of their IVF culture media is no longer an option for clinical embryologists,” Hans Evers, editor in chief of Human Reproduction, wrote in an accompanying editorial.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.